ESR1 fusions and therapeutic resistance in metastatic breast cancer. | Front Oncol;12: 1037531, 2022. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

ESR1 fusions and therapeutic resistance in metastatic breast cancer.

Nagy, Zsuzsanna; Jeselsohn, Rinath.

Affiliation

Nagy Z; Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
Jeselsohn R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

Front Oncol ; 12: 1037531, 2022.

Article in En | MEDLINE | ID: mdl-36686845

Key words

ESR1 fusion; SERD; breast cancer; endocrine therapy resistance; estrogen receptor

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2022 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2022 Document type: Article Affiliation country: Country of publication: